cirrhosis diagnosis. Furthermore, the posttreatment parameters of the AFP level 1 tolica del Sacro Cuore, Rome, Italy. month after PEI and recurrence of HCC in the same liver segment were also 2 Divisione di Gastroenterologia, IRCCS Casa evaluated. Sollievo della Sofferenza, San Giovanni Rotondo #
Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma
β Scribed by Masahiko Koda; Yoshikazu Murawaki; Akeri Mitsuda; Kenji Ohyama; Yutaka Horie; Takeaki Suou; Hironaka Kawasaki; Shiro Ikawa
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 140 KB
- Volume
- 88
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
BACKGROUND.
Percutaneous ethanol injection therapy has been used widely for small hepatocellular carcinoma. This study was undertaken to determine factors predictive of local recurrence or new nodular recurrence in patients with small hepatocellular carcinoma treated with percutaneous ethanol injection.
METHODS.
The authors studied 73 nodules treated with percutaneous ethanol injection in 49 patients with small hepatocellular carcinoma. The usefulness of predictive factors for recurrence was assessed with the Kaplan-Meier method. The clinicopathologic variables examined included age, gender, Child-Pugh classification, number of tumors (single vs. multiple), tumor size, degree of tumor differentiation, ultrasonographic findings such as peripheral hypoechoic band (so-called ΠhaloΠ), intratumoral echo pattern, tumor staining on enhanced computed tomography, combination therapy with transcatheter arterial embolization, and serum β£-fetoprotein level.
RESULTS.
The local recurrence rates were 19%, 27%, 33%, 33%, and 33%, respectively, and the new nodular recurrence rates were 19%, 51%, 74%, 83%, and 83%, respectively, at 1, 2, 3, 4, and 5 years after percutaneous ethanol injection therapy.
The frequency of local recurrence was associated with the histologic differentiation of more than moderately differentiated (P Ο½ 0.001), presence of a sonographic halo (P Ο½ 0.005), an intratumoral heterogeneous echo pattern (P Ο½ 0.001), and positive tumor staining on enhanced computed tomography (P Ο½ 0.01). Multivariate analysis showed that the presence of a halo and an intratumoral heterogeneous echo pattern were the most important variables for predicting local recurrence. The frequency of new nodular recurrences was related to the presence of multiple tumors (P Ο½ 0.01) and a high serum β£-fetoprotein level (P Ο½ 0.001). Multivariate analysis showed that a high serum β£-fetoprotein level was a reliable predictor of new nodular recurrence.
CONCLUSIONS.
This study showed that the presence of a halo and an intratumoral echo pattern on ultrasonography were useful predictors for local recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma, and that a high serum β£-fetoprotein level was associated with a higher frequency of new nodular recurrences.
π SIMILAR VOLUMES
## Background: In japan, where liver transplantation has not been used to treat patients with hepatocellular carcinoma (hcc), percutaneous ethanol injection (pei) has been employed for those with small hccs that are not amenable to surgical resection. in the current study, the authors evaluated pei
## BACKGROUND. The authors compared the efficacy of percutaneous microwave coagulation therapy (PMCT) and percutaneous ethanol injection therapy (PEIT) in the treatment of patients with cirrhosis and a solitary nodular hepatocellular carcinoma (HCC) Υ 2 cm in greatest dimension. ## METHODS. Of
## Background: The objective of this study was to identify clinical, biochemical, ultrasound, and/or pathologic parameters capable of predicting survival in a cohort of patients with well compensated cirrhosis and small hepatocellular carcinoma (hcc) who were treated with percutaneous ethanol injec